ReviewFrontiers in cell and developmental biology2025
Efferocytosis: a therapeutic strategy for diabetes and its vascular complications.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efferocytosis: unifying pathogenic hub in metabolic disorders-mechanistic landscapes, targeted therapies and translational bottlenecks.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Efferocytosis is a continuous multistep process that efficiently clears dead cells and is essential for maintaining homeostasis in multicellular organisms. Under normal circumstances, apoptotic cells release "find-me" and "eat-me" signals that stimulate their engulfment and clearance. However, in many chronic inflammatory diseases, the clearance of apoptotic cells is significantly impaired. This review explores the relationship between defective efferocytosis and diabetes-related vascular complications, while investigating underlying pathophysiological mechanisms to identify novel therapeutic targets for disease management. Methods: After searching in PubMed and Web of Science databases using 'efferocytosis', 'diabetic vascular complications', and 'efferocytosis-based therapy' as keywords, studies related were compiled and examined. Results: This review summarizes the specific process of phagocytes engulfing and clearing dead cells, and explains the development of diabetes and its vascular complications from the perspective of defects in efferocytosis. Conclusion: The review points out that molecules and pathways associated with efferocytosis are potential targets for treating diabetic vascular complications, providing new ideas for clinical treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.